HomeCompareOLMIY vs JNJ

OLMIY vs JNJ: Dividend Comparison 2026

OLMIY yields 47.49% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OLMIY wins by $32.62M in total portfolio value
10 years
OLMIY
OLMIY
● Live price
47.49%
Share price
$25.02
Annual div
$11.88
5Y div CAGR
23.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.65M
Annual income
$21,855,504.05
Full OLMIY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — OLMIY vs JNJ

📍 OLMIY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOLMIYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OLMIY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OLMIY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OLMIY
Annual income on $10K today (after 15% tax)
$4,036.82/yr
After 10yr DRIP, annual income (after tax)
$18,577,178.44/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, OLMIY beats the other by $18,573,192.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OLMIY + JNJ for your $10,000?

OLMIY: 50%JNJ: 50%
100% JNJ50/50100% OLMIY
Portfolio after 10yr
$16.34M
Annual income
$10,930,096.73/yr
Blended yield
66.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OLMIY
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OLMIY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOLMIYJNJ
Forward yield47.49%2.13%
Annual dividend / share$11.88$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.7%28%
Portfolio after 10y$32.65M$30.3K
Annual income after 10y$21,855,504.05$4,689.40
Total dividends collected$31.54M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OLMIY vs JNJ ($10,000, DRIP)

YearOLMIY PortfolioOLMIY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$16,575$5,874.77$10,592$272.30+$6.0KOLMIY
2$28,992$11,257.04$11,289$357.73+$17.7KOLMIY
3$53,785$22,763.62$12,123$472.89+$41.7KOLMIY
4$106,371$48,821.42$13,141$629.86+$93.2KOLMIY
5$225,442$111,624.51$14,408$846.81+$211.0KOLMIY
6$514,722$273,498.60$16,021$1,151.60+$498.7KOLMIY
7$1,272,655$721,902.52$18,122$1,588.22+$1.25MOLMIY
8$3,425,232$2,063,491.49$20,930$2,228.20+$3.40MOLMIY
9$10,085,486$6,420,488.06$24,792$3,191.91+$10.06MOLMIY
10$32,646,974$21,855,504.05$30,274$4,689.40+$32.62MOLMIY

OLMIY vs JNJ: Complete Analysis 2026

OLMIYStock

Olam Group Limited engages in the sourcing, processing, packaging, and merchandising of agricultural products worldwide. It operates through Olam Food Ingredients, Olam Global Agri, and Olam International Limited segments. The company offers cocoa powder, liquor, and butter, as well as specialty fats, such as vegetable fats, cocoa butter equivalent fats, cocoa butter improver fats, cocoa butter substitutes, and confectionery and custom fats under the under the deZaan, Unicao, Joanes, Macao, Huysman, Britannia, and BT Cocoa brands; coffee; whole, skimmed, and butter milk powders; butter, anhydrous milk fat, and butter blends; cheese; milk and whey protein concentrates, permeates, and lactose; nuts, including almonds, cashews, hazelnuts, peanuts, sesame, and quinoa and chia seeds; and spices, comprising of chillies, onion and garlic, and pepper. It also provides cotton; palm, soybean, and sunflower oils; animal feeds and proteins; flours for breads, baguettes, pasta noodles, biscuits, semolina, and confectionery; fish feeds; rubber; rice; and timber products. In addition, the company offers biscuits under the Perk, King Cracker, Pure Bliss, and Chic Choc brands; tomato mix under the Tasty Tom, De Rica, and Festin brand names; Tasty Tom Jollof Mix; drinking yoghurt under the FreshYo brand; lollipops under the OK Pop brand name; and noodles under the Cherie Noodles, Cherie Supa Chicken, and Tasty Tom brands. Further, the company engages in the poultry breeding farm and day-old-chick hatchery business; and provision of commodity financial, risk management, and infrastructure and logistics services, as well as sourcing solutions for agricultural raw materials and food ingredients. Olam Group Limited was founded in 1989 and is headquartered in Singapore.

Full OLMIY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this OLMIY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OLMIY vs SCHDOLMIY vs JEPIOLMIY vs OOLMIY vs KOOLMIY vs MAINOLMIY vs ABBVOLMIY vs MRKOLMIY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.